Starting with the launch of the Human Genome Project three decades ago, and continuing
after its completion in 2003, genomics has progressively come to have a central and …

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly
polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism …

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele
nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation …

The poor predictability of human liver toxicity is still causing high attrition rates of drug
candidates in the pharmaceutical industry at the non-clinical, clinical, and post-marketing …

The goals of the Association for Molecular Pathology Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …

CYP2D6 genotype is increasingly being integrated into practice to guide prescribing of
certain medications. The CYP2D6 drug metabolizing enzyme is susceptible to inhibition by …

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele
nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the …

Psychiatric genomics is providing insights into the nature of psychiatric conditions that in
time should identify new drug targets and improve patient care. Less attention has been paid …

Clinical decision support (CDS) is an essential part of any pharmacogenomics (PGx)
implementation. Increasingly, institutions have implemented CDS tools in the clinical setting …

Genetic testing has evolved rapidly over recent years and new developments have the
potential to provide insights that could improve the ability to diagnose, treat, and prevent …